Last updated: February 19, 2026
This report analyzes the patent litigation between AstraZeneca AB and Zydus Pharmaceuticals (USA), Inc., concerning Zydus's Abbreviated New Drug Application (ANDA) for a generic version of AstraZeneca's Symbicort (budesonide and formoterol fumarate dihydrate) inhaler. The core dispute revolves around the alleged infringement of AstraZeneca's U.S. Patent No. 7,750,060, which claims a specific formulation of budesonide and formoterol fumarate dihydrate in a metered-dose inhaler.
What is the Central Patent in Dispute?
The primary patent at issue is U.S. Patent No. 7,750,060. This patent, titled "Metered dose inhaler device and formulation for the treatment of asthma and COPD," was issued on July 6, 2010. AstraZeneca is the assignee. The patent claims a formulation comprising specific amounts of budesonide and formoterol fumarate dihydrate, along with a propellant and a surfactant, intended for use in a metered-dose inhaler. The claims of the '060 patent are directed to both the formulation itself and its use in treating asthma and chronic obstructive pulmonary disease (COPD).
What is the Alleged Infringing Product?
Zydus Pharmaceuticals (USA), Inc. is seeking approval for a generic version of Symbicort 160/4.5 mcg, a metered-dose inhaler. This product, if approved and marketed, would compete directly with AstraZeneca's branded Symbicort. Zydus filed an ANDA with the U.S. Food and Drug Administration (FDA) seeking to market its generic equivalent.
What are AstraZeneca's Claims Against Zydus?
AstraZeneca's primary claim is that Zydus's proposed generic product infringes U.S. Patent No. 7,750,060. AstraZeneca alleges that Zydus's ANDA product contains the same active pharmaceutical ingredients (APIs) in a similar formulation and is intended for the same therapeutic uses as described and claimed in the '060 patent. AstraZeneca contends that the manufacture, use, offer for sale, sale, and importation of Zydus's generic Symbicort product would infringe one or more claims of the '060 patent.
What is Zydus's Defense Strategy?
Zydus's defense is centered on challenging the validity and enforceability of AstraZeneca's U.S. Patent No. 7,750,060. The company asserts that the patent is invalid and/or not infringed by its proposed generic product. Specific defenses typically raised in such Hatch-Waxman litigation include:
- Non-Infringement: Zydus argues that its generic formulation does not fall within the scope of the claims of the '060 patent. This could involve arguments about differences in the exact composition, particle size, or performance characteristics of the inhaler device.
- Invalidity: Zydus challenges the patent's validity on grounds such as:
- Obviousness: The invention claimed in the '060 patent was obvious to a person of ordinary skill in the art at the time of filing, based on prior art references.
- Lack of Enablement/Written Description: The patent does not adequately describe the invention or teach a person skilled in the art how to make and use the full scope of the claimed invention.
- Anticipation: The claimed invention is not novel and was already disclosed in the prior art.
What is the Procedural History of the Case?
The litigation was initiated by AstraZeneca filing a complaint against Zydus in the United States District Court for the District of Delaware. The case number is 1:21-cv-00550. AstraZeneca sought a preliminary and permanent injunction to prevent Zydus from launching its generic product. The court proceedings typically involve claim construction (interpreting the meaning of patent claims), discovery (exchanging information and evidence), expert witness reports, and potentially a bench trial or settlement.
What is the Status of the Litigation?
As of the most recent available information, the litigation between AstraZeneca AB and Zydus Pharmaceuticals (USA), Inc. concerning U.S. Patent No. 7,750,060 is ongoing. The court is likely engaged in the standard phases of Hatch-Waxman litigation, which can include claim construction hearings, discovery disputes, and preparation for trial. The specific stage of proceedings, such as whether a trial date has been set or if summary judgment motions have been filed, would require a detailed review of the most current court dockets.
What are the Potential Outcomes of the Litigation?
The outcome of this litigation carries significant commercial implications. Potential outcomes include:
- AstraZeneca Prevails: If the court finds that Zydus infringes the '060 patent and that the patent is valid, Zydus will be blocked from launching its generic product for the remaining term of the patent. This would allow AstraZeneca to continue selling Symbicort without direct generic competition.
- Zydus Prevails: If the court finds that Zydus does not infringe the patent or that the patent is invalid, Zydus may receive FDA approval and launch its generic product. This would lead to significant price erosion for Symbicort.
- Settlement: The parties may reach a confidential settlement agreement. Such agreements often involve Zydus agreeing to delay its launch in exchange for certain considerations from AstraZeneca, such as a licensing agreement or a supply arrangement.
- Partial Victory: It is possible that Zydus may succeed in invalidating certain claims of the patent while being found to infringe others, or vice versa, leading to a more complex resolution.
What are the Commercial Implications for AstraZeneca and Zydus?
The commercial stakes are substantial. For AstraZeneca, a successful defense of the '060 patent would extend the market exclusivity of its blockbuster drug Symbicort, which generated billions in revenue. For Zydus, a favorable outcome would grant market entry for its generic product, enabling it to capture a significant share of the Symbicort market. The market for respiratory inhalers is large, and generic competition typically leads to drastic price reductions, impacting both brand and generic manufacturers.
Key Takeaways
- AstraZeneca AB is litigating U.S. Patent No. 7,750,060 against Zydus Pharmaceuticals (USA), Inc.
- The patent covers a specific formulation of budesonide and formoterol fumarate dihydrate for metered-dose inhalers, the active ingredients in Symbicort.
- Zydus seeks to market a generic version of Symbicort via an ANDA filing.
- AstraZeneca alleges patent infringement, while Zydus asserts patent invalidity and non-infringement.
- The litigation is proceeding in the U.S. District Court for the District of Delaware.
- The outcome will determine Zydus's ability to launch its generic product and impact Symbicort's market exclusivity.
Frequently Asked Questions
-
When does U.S. Patent No. 7,750,060 expire?
The expiration date of U.S. Patent No. 7,750,060 is July 6, 2027, absent any extensions or adjustments. This date is a critical factor in the litigation's financial impact.
-
Has Zydus received tentative or final approval from the FDA for its generic Symbicort?
FDA approval status is typically contingent on the outcome of patent litigation. Zydus's ANDA would likely be subject to a 30-month stay imposed by the Hatch-Waxman Act if a patent infringement suit is filed within a specific timeframe. Final approval is unlikely until patent issues are resolved or the stay expires.
-
Are there other AstraZeneca patents for Symbicort that Zydus might face litigation over?
Pharmaceutical companies often list multiple patents for a single drug product in the FDA's Orange Book. While U.S. Patent No. 7,750,060 appears to be the primary patent in this specific litigation, AstraZeneca may hold other patents related to Symbicort's formulation, device, or method of use. However, these are not the subject of the current 1:21-cv-00550 case.
-
What is the typical duration of Hatch-Waxman patent litigation?
Hatch-Waxman litigation can be lengthy, often spanning two to four years from filing to final resolution, although this can vary depending on the complexity of the patents, the number of patents involved, and procedural factors.
-
What is the significance of the "160/4.5 mcg" designation in the context of this litigation?
The "160/4.5 mcg" refers to the specific dosage of the active ingredients per actuation: 160 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate. AstraZeneca alleges that Zydus's ANDA product for this specific strength infringes the '060 patent claims, which are also directed to formulations with these or comparable therapeutic amounts.
Cited Sources
[1] United States District Court for the District of Delaware. (n.d.). AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc. Case No. 1:21-cv-00550. (Information accessed via public court dockets).
[2] U.S. Patent No. 7,750,060. (2010). Metered dose inhaler device and formulation for the treatment of asthma and COPD. Washington, DC: U.S. Patent and Trademark Office.
